The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

Study researchers spotted the spike in liver enzymes, or liver transaminitis, among people who received BioAge’s drug either as monotherapy or in combination with tirzepatide, which Lilly sells as ...

Eli Lilly and Company announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ...